Japan Fair Trade Commission On-Site Inspection Concerning Suspected Antimonopoly Act Violations
First written in FY2020-Q3. 5 of 15 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「Meanwhile, this was due to a ¥4,937 million decrease in the provision for antitrust-related losses.」
The provision for antitrust-related losses decreased from ¥4,937 million at the end of the previous fiscal year and was not recognized on the balance sheet at the end of the fiscal year ending March 2026. - FY2026-H1Antitrust-related provision decreasedAnnual report
「“Provision for losses related to the Antimonopoly Act” decreased by ¥4.937 billion」
The provision for antitrust-related losses decreased from ¥4,937 million at the end of the previous fiscal year and was not recognized on the balance sheet at the end of the interim period. This was disclosed as a change in the provision balance related to existing matters. - FY2025RestatedAnnual report
「Provision for antitrust-related losses: ¥4,937 million」
The Company continued to recognize ¥4,937 million in provision for losses related to the Antimonopoly Act violation, as in the previous fiscal year, and continues to address losses reasonably estimated in respect of amounts equivalent to contractual penalties. - FY2023MaterialisedAnnual report
「Consolidated subsidiary アルフレッサ株式会社 underwent an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act in tenders and other proceedings conducted by the headquarters of the National Hospital Organization (NHO) from 20 May 2016 to 3 June 2019 concerning pharmaceuticals procured by hospitals located in the Kyushu Area operated by either NHO or the Japan Organization of Occupational Health and Safety (JOHAS), and in March 2023 received a cease-and-desist order and a surcharge payment order from the Commission.」
Regarding the investigation into NHO and JOHAS tenders in the Kyushu Area, the Japan Fair Trade Commission issued a cease-and-desist order and a surcharge payment order in March 2023, causing the risk to materialize as administrative sanctions. - FY2023-Q2RestatedAnnual report
「On 9 November 2021, consolidated subsidiary アルフレッサ株式会社 underwent an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act in tenders and other proceedings conducted by the headquarters of the National Hospital Organization (NHO) concerning pharmaceuticals procured by hospitals located in the “Kyushu Area” operated by either NHO or the Japan Organization of Occupational Health and Safety (JOHAS).」
The Company continues to disclose the Japan Fair Trade Commission’s on-site inspection concerning NHO and JOHAS tenders in the Kyushu Area and the fact that the impact cannot be reasonably estimated. - FY2023-Q1The period of suspension from tendering endedAnnual report
「Revenue increased due to market growth and the end of the period of suspension from tendering by medical institutions imposed for violating the Antimonopoly Act, among other factors.」
The period of suspension from tendering by medical institutions imposed in connection with the Antimonopoly Act violation ended, contributing to higher revenue in the wholesale prescription drug business. Meanwhile, the Japan Fair Trade Commission’s on-site inspection concerning NHO and JOHAS tenders in the Kyushu Area is continuing. - FY2022-Q3RestatedAnnual report
「In November 2021, アルフレッサ was also subject to an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act in connection with bids and other matters conducted by the headquarters of the National Hospital Organization for pharmaceuticals procured by hospitals located in the Kyushu area operated by the National Hospital Organization (NHO) or the Japan Organization of Occupational Health and Safety (JOHAS).」
The guilty verdict and finalization of the fine concerning the JCHO tender, together with the on-site inspection concerning NHO and JOHAS tenders in the Kyushu Area, are described as ongoing antitrust-related matters. - FY2022-Q2WorsenedAnnual report
「On 9 November 2021, consolidated subsidiary アルフレッサ株式会社 underwent an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act in tenders and other proceedings conducted by the headquarters of the National Hospital Organization (NHO) concerning pharmaceuticals procured by hospitals located in the “Kyushu Area” operated by either NHO or the Japan Organization of Occupational Health and Safety (JOHAS).」
Separately from the JCHO matter, the Company disclosed that it had also undergone a Japan Fair Trade Commission on-site inspection concerning tenders and other proceedings for hospitals in the Kyushu Area operated by NHO or JOHAS, broadening the scope of the antitrust investigation. - FY2022-Q2MaterialisedAnnual report
「In June 2021, consolidated subsidiary アルフレッサ株式会社 (headquartered in Chiyoda-ku, Tokyo; hereinafter “アルフレッサ”) received a guilty verdict from the Tokyo District Court for violating the Antimonopoly Act in a prescription drug tender for which the National Hospital Organization of Japan Community Health Care Organization (JCHO) was the procuring entity, and the ¥250 million fine became final in July of the same year.」
Regarding the violation of the Antimonopoly Act in connection with the JCHO tender, the previously disclosed fine imposed under the guilty verdict became final in July 2021. - FY2022-Q1MaterialisedAnnual report
「In June 2021, Alfresa Corporation, a consolidated subsidiary headquartered in Chiyoda-ku, Tokyo, received a guilty verdict from the Tokyo District Court and a fine of ¥250 million for violating the Antimonopoly Act in a tender for prescription drugs ordered by the Japan Community Health Care Organization (JCHO).」
Regarding the violation of the Antimonopoly Act in connection with the JCHO tender disclosed since the previous fiscal year, the consolidated subsidiary received a guilty verdict and was fined ¥250 million. - FY2021RestatedAnnual report
「Consolidated subsidiary アルフレッサ株式会社 and its employees and others were indicted by the Tokyo District Public Prosecutors Office on suspicion of violating the Antimonopoly Act in a prescription drug tender for which the National Hospital Organization of Japan Community Health Care Organization (JCHO) was the procuring entity.」
The Company continues to disclose the indictment of the consolidated subsidiary and its employees and others concerning suspected violations of the Antimonopoly Act in connection with JCHO’s prescription drug tender. - FY2021-Q3MaterialisedAnnual report
「In December 2020, consolidated subsidiary アルフレッサ株式会社 (headquartered in Chiyoda-ku, Tokyo; hereinafter “アルフレッサ”) was indicted by the Tokyo District Public Prosecutors Office on suspicion of violating the Antimonopoly Act in a prescription drug tender for which the National Hospital Organization of Japan Community Health Care Organization (JCHO) was the procuring entity.」
Regarding the on-site inspection and search disclosed since the previous fiscal year, the consolidated subsidiary was indicted by the Tokyo District Public Prosecutors Office. The quarterly net income or loss also includes ¥4,567 million in provision for antitrust-related losses. - FY2021-Q2WorsenedAnnual report
「The consolidated subsidiary アルフレッサ株式会社 was subject to an on-site inspection by the Japan Fair Trade Commission on 27 November 2019, and a search by the Tokyo District Public Prosecutors Office and the Commission on 13 October 2020, on suspicion of violating the Antimonopoly Act in connection with bids for prescription pharmaceuticals ordered by the Japan Community Health care Organization (JCHO).」
In addition to the Japan Fair Trade Commission’s on-site inspection concerning JCHO’s prescription drug tender, the Company disclosed that it had also been searched by the Tokyo District Public Prosecutors Office and the Commission, indicating that the investigation has expanded. - FY2021-Q1RestatedAnnual report
「On 27 November 2019, the consolidated subsidiary アルフレッサ株式会社 was subject to an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act in connection with bids for prescription pharmaceuticals conducted by the Japan Community Health care Organization (JCHO).」
The company continues to disclose the Japan Fair Trade Commission’s on-site inspection in connection with a JCHO tender for prescription drugs and the ongoing situation in which the amount of the impact cannot reasonably be estimated. - FY2020-Q3First statedAnnual report
「On 27 November 2019, Alfresa Co., Ltd., a consolidated subsidiary of the company, was subject to an on-site inspection by the Japan Fair Trade Commission on suspicion of violating the Antimonopoly Act in connection with a tender for prescription drugs conducted by the Japan Community Health care Organization (JCHO), an incorporated administrative agency. The investigation could affect consolidated results, but as it is ongoing, the potential amount of the impact cannot reasonably be estimated at this time.」
A consolidated subsidiary was subject to an on-site inspection by the Japan Fair Trade Commission in connection with a JCHO tender for prescription drugs. The company has indicated that consolidated results could be affected, but the investigation is ongoing and the amount of the impact cannot reasonably be estimated.